SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

CIFR is trending as anticipation builds around a potential high-performance computing (HPC) deal, possibly with a major player like Oracle, driving bullish sentiment. Community members are actively discussing potential price targets and the company's prospects in the AI data center space, drawing comparisons to sector peers. Some traders speculate about an imminent announcement, while others cite the company's strong positioning within the AI infrastructure landscape as a reason for optimism.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending as the community speculates on a potential hyperscaler deal and its ties to Nvidia's AI initiatives, driving significant price movement. Talk centers around potential partnerships and anticipation of substantial upside due to secured contracts amid growing AI infrastructure demand. Some traders are also highlighting potential short squeeze opportunities.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending amid high short interest and borrow fees, sparking discussions of a potential short squeeze. Community members are debating whether a large shareholder will trigger a squeeze, while others highlight the stock's volatility and potential for both significant gains and losses. The stock's connection to a well-known investor and its standing on short squeeze leaderboards are also driving interest.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is trending as the community debates whether it represents a value opportunity or a value trap, with some citing its low P/E ratio and high dividend yield. Discussions include TRC Capital's mini-tender offer and speculation about potential catalysts like Taylor Swift's new album, while others express concern over falling sales and overall market performance.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co.

Walt Disney Co. is trending as community members react to news of Jimmy Kimmel's show returning, sparking debates about free speech, censorship, and the company's direction. Some investors express concerns about Disney potentially alienating portions of its audience, while others see a buying opportunity amidst the controversy. The stock's long-term potential is also being weighed against immediate market reactions within the context of the broader streaming landscape.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's stock is seeing mixed sentiment as investors debate its near-term direction, while noting the company is lagging behind other mega-cap tech stocks this year. Some traders express frustration with the stock's intraday price action and overall performance, while others are discussing potential catalysts like upcoming earnings and a possible resolution to the FTC trial over Prime subscriptions. The community is also weighing the potential impact of new H-1B visa regulations.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai ($BBAI) is trending as the community discusses its potential for a short squeeze and anticipates upcoming news or contracts.  Bullish sentiment is fueled by the stock's recent price action, high trading volume, and perceived government ties.  Many are focused on key price levels and expressing optimism about the company's prospects in the AI and national security sectors.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is trending following news of its acquisition of Paige, a leader in digital pathology, aimed at enhancing AI-powered cancer diagnostics. Community discussions revolve around the potential impact of this acquisition on Tempus's market position and its broader strategy in the AI healthcare space.  However, some are expressing concern over insider selling and the valuation of the stock.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

Better Home & Finance Holding Co. is trending as community members discuss a potential pump and dump scheme following comments from a hedge fund manager comparing it to Shopify, with a potential upside of "350x in 2 years".  The conversation includes both bullish and bearish sentiment, with some drawing comparisons to hedge fund manager Eric Jackson's previous promotion of Opendoor. Community members are also actively analyzing warrant pricing and the potential for a short squeeze due to the low float.

AgriFORCE Growing Systems Ltd. is an agriculture technology company, which engages in the development and utilization of intellectual property (IP) assets for improvement. Its solutions include consulting, air and surface sterilization, and other projects. The company was founded on December 22, 2017 and is headquartered in Vancouver, Canada.

AgriFORCE Growing Systems ltd

AGRI is trending due to news of a potential $550M capital raise and rebranding as AVAX One, an Avalanche-focused company, sparking high trading volume and a battle between longs and shorts. The community is discussing the potential for a squeeze given the low float, while also debating the legitimacy of the move and the company's future prospects. Technical traders are watching key resistance levels and assessing if a trend reversal is underway.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround 

The heavy selling pressure might have exhausted for Spero Therapeutics (SPRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease

BAYRY begins human trials for OpCT-001, an experimental cell therapy for treating primary photoreceptor diseases.

AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer

AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.

Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.

RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance

FDA clears Rocket Pharmaceuticals' IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.

ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B

AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.

Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why

The VOR stock soars in the past week after a licensing deal with RemeGen. The company also appoints a chief executive officer and chairman.

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

British pharmaceutical company GSK PLC (GSK) and its Massachusetts-based partner Spero Therapeutics (SPRO) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gsk.com/en-gb/media/press-releases/pivot-po-phase-iii-study-for-tebipenem-hbr-stopped-early-for-efficacy-following-review-by-independent-data-monitoring-committee/">said</a> on Wednesday that they are stopping their late-stage trial evaluating the efficacy of its investigational oral treatment for complicated urinary tract infections (cUTI) earlier than expected following positive results.The treatment, called Tebipenem Pivoxil Hydrobromide (HBr), was developed by GSK and Spero. In September 2022, GSK entered into an exclusive license agreement with Spero Therapeutics for the development and commercialisation of Tebipenem HBr in all markets, except certain Asian territories.The early stop follows the trial meeting its primary goal of showing non-inferiority of Tebipenem HBr compared to an intravenous medicine in hospitalized adult patients with cUTI, including Pyelonephritis, where the infection spreads from the bladder to the kidneys.The decision follows a recommendation from an Independent Data Monitoring Committee (IDMC), based on an analysis of data from 1,690 patients enrolled in the study. The committee did not identify any new safety concerns beyond what has been reported in other studies with Tebipenem, the companies said.GSK said that it plans to work with U.S. regulatory authorities to include the data as part of a filing in the second half of the year.If approved, Tebipenem HBr would be the first oral carbapenem antibiotic for patients in the U.S. who suffer from cUTIs, GSK said. An estimated 2.9 million cases of cUTIs are treated annually in the U.S. alone, the company noted.The current standard of care for cUTIs includes carbapenem antibiotics, which are available for intravenous administration, requiring emergency department visits and hospitalization.SPRO stock rocketed 203% on Wednesday morning following the news, while NYSE-listed shares of GSK fell marginally.On Stocktwits, retail sentiment around SPRO jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘extremely high’ levels. &nbsp;<figure class="image"><img style="aspect-ratio:623/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_28_at_9_09_53_AM_png_aff7b11b53.webp" alt="SPRO's Sentiment Meter and Message Volume as of 9:10 a.m. ET on May 28, 2025 | Source: Stocktwits " width="623" height="63"><figcaption>SPRO's Sentiment Meter and Message Volume as of 9:10 a.m. ET on May 28, 2025 | Source: Stocktwits&nbsp;</figcaption></figure>Meanwhile, retail sentiment around GSK rose from ‘neutral’ to ‘bullish’ territory, coupled with ‘low’ message volume.<figure class="image"><img style="aspect-ratio:626/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_28_at_9_11_15_AM_png_bcb11bf986.webp" alt="GSK's Sentiment Meter and Message Volume as of 9:10 a.m. ET on May 28, 2025 | Source: Stocktwits " width="626" height="66"><figcaption>GSK's Sentiment Meter and Message Volume as of 9:10 a.m. ET on May 28, 2025 | Source: Stocktwits&nbsp;</figcaption></figure><a href="https://stocktwits.com/symbol/SPRO">SPRO stock</a> is up by about 94% this year, while <a href="https://stocktwits.com/symbol/GSK">GSK shares</a> are up by about 16%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/abercrombie-and-fitch-post-strong-q1-2025-earnings/ch0oSjCRbsQ">Abercrombie &amp; Fitch Stock Soars After Upbeat Q1 Results: Retail Turns More Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled

The early stop follows the trial meeting its primary endpoint of non-inferiority of Tebipenem HBr compared to an intravenous medicine in hospitalised adult patients with cUTI.

Equity

The early stop follows the trial meeting its primary endpoint of non-inferiority of Tebipenem HBr compared to an intravenous medicine in hospitalised adult patients with cUTI, including Pyelonephritis, where the infection spreads from the bladder to the kidneys. 


Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Spero Therapeutics Inc

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

Current Price	$2.02
Prev Close	$2.00
Open	$2.00
Dividend Yield	0.00%
50-Day Moving Average	$2.13
Beta	0.72
Avg. Volume	711,565.71
PE Ratio	-2.04

52-Week High	$3.22
52-Week Low	$0.5052
Market Capitalization	$112.55M
EPS (Annual)	-$1.27
Price to Book	3.42
Revenue Per Employee	$856,125.00
Enterprise Value/EBITDA	N/A

SPRO
Spero Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SPRO News

SPRO Spero Therapeutics Inc